A series of cardiometabolic-related news items have been observed from Novo Nordisk, Biomea Fusion, and EMA. Below, FENIX provides highlights and insights for the respective news items.
On the third day of ATTD 2025, five cardiometabolic-related news items have been observed from Novo Nordisk, Skye Bioscience, Terns Pharmaceuticals, Allurion Technologies, and Alnylam Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related events has been observed from FDA, Viking Therapeutics, Roche, and Halia Therapeutics/Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, BI, Mineralys Therapeutics, and Insulet. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Novo Nordisk announced it launched NovoCare and decreased Wegovy to $499/month, competing with Lilly’s LillyDirect model (view press release); Lilly has opened bids for US states to court Lilly manufacturing investments (view article; view website); and Lilly initiated the Ph3 TRIUMPH-6 retatrutide obesity maintenance study (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items, including thoughts on how NovoCare is following Lilly’s lead for the new US commercial model.
A series of cardiometabolic-related news items has been observed from Lilly, Novo Nordisk, Senseonics, Esperion, and Fractyl Health. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed: AbbVie and Gubra announced a licensing agreement for a QW SC LA amylin agonist in obesity (view press release); Novo Nordisk and Gensaic entered into a new AI partnership for drug discovery (view press release); and Biocon has initiated a limited launch for its generic liraglutide in the UK (view press release). Below, FENIX provides highlights and insights for the respective news items
Two cardiometabolic-related news items have been observed: Lilly has stockpiled $548M worth of orforglipron in a risky move ahead of the regulatory filing/approval (view 10-K); and the CHMP agenda (view here) for this month’s meeting (Feb 24-27) has been released. Below, FEINX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Novo Nordisk, Viking Therapeutics/Pfizer, and Insulet. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Novo Nordisk, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, and Oramed Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.